Journal ArticleDOI
The eczema area and severity index (EASI): assessment of reliability in atopic dermatitis
Jon M. Hanifin,Thurston M,Thurston M,Omoto M,Omoto M,R. Cherill,R. Cherill,Susan J. Tofte,Graeber M,Graeber M +9 more
Reads0
Chats0
TLDR
In this paper, the reliability of the EASI scoring system was evaluated by assessing inter-and intra-observer consistency, and the results indicated that the evaluators assessed the patients consistently across both study days.Abstract:
:Objective– To test the reliability of the eczema area and severity index (EASI) scoring system by assessing inter- and intra-observer consistency. Design: Training of evaluators, application, and assessment over 2 consecutive days. Setting– An academic center. Patients– Twenty adults and children with atopic dermatitis (AD); cohort 1 (10 patients ≥8 years) and cohort 2 (10 patients <8 years). Interventions– None. Main outcome measure– The EASI was used by 15 dermatologist evaluators to assess atopic dermatitis in cohort 1 and cohort 2 on 2 consecutive days. Inter- and intraobserver reliability were analyzed. Results– Overall intra-evaluator reliability of the EASI was in the fair-to-good range. Inter-evaluator reliability analyses indicated that the evaluators assessed the patients consistently across both study days. Conclusions– This study demonstrated that the EASI can be learned quickly and utilized reliably in the assessment of severity and extent of AD. There was consistency among the evaluators between consecutive days of evaluation. These results support the use of the EASI in clinical trials of therapeutic agents for AD.read more
Citations
More filters
Journal ArticleDOI
Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis
Eric L. Simpson,Thomas Bieber,Emma Guttman-Yassky,Lisa A. Beck,Andrew Blauvelt,Michael J. Cork,Jonathan I. Silverberg,Mette Deleuran,Yoko Kataoka,Jean-Philippe Lacour,Külli Kingo,Margitta Worm,Margitta Worm,Yves Poulin,Andreas Wollenberg,Yuhwen Soo,Neil M.H. Graham,Gianluca Pirozzi,Bolanle Akinlade,Heribert Staudinger,Vera Mastey,Laurent Eckert,Abhijit Gadkari,Neil Stahl,George D. Yancopoulos,Marius Ardeleanu +25 more
TL;DR: Dupilumab improved the signs and symptoms of atopic dermatitis, including pruritus, symptoms of anxiety and depression, and quality of life, as compared with placebo in two phase 3 trials of identical design.
Journal ArticleDOI
Dupilumab treatment in adults with moderate-to-severe atopic dermatitis.
Lisa A. Beck,Diamant Thaçi,Jennifer D. Hamilton,Neil M.H. Graham,Thomas Bieber,Ross E. Rocklin,Jeffrey Ming,Haobo Ren,Richard Kao,Eric L. Simpson,Marius Ardeleanu,Steven P. Weinstein,Gianluca Pirozzi,Emma Guttman-Yassky,Mayte Suárez-Fariñas,Melissa D. Hager,Neil Stahl,George D. Yancopoulos,Allen Radin +18 more
TL;DR: Patients treated with dupilumab had marked and rapid improvement in all the evaluated measures of atopic dermatitis disease activity, and side-effect profiles were not dose-limiting.
Journal ArticleDOI
Guidelines of care for the management of atopic dermatitis: section 1. Diagnosis and assessment of atopic dermatitis.
Lawrence F. Eichenfield,Wynnis L. Tom,Sarah L. Chamlin,Steven R. Feldman,Jon M. Hanifin,Eric L. Simpson,Timothy G. Berger,James N. Bergman,David E. Cohen,Kevin D. Cooper,Kelly M. Cordoro,Dawn Marie R. Davis,Alfons Krol,David J. Margolis,Amy S. Paller,Kathryn Schwarzenberger,Robert A. Silverman,Hywel C Williams,Craig A. Elmets,Julie Block,Christopher G. Harrod,Wendy Smith Begolka,Robert Sidbury +22 more
TL;DR: This guideline addresses important clinical questions that arise in the management and care of AD, providing updated and expanded recommendations based on the available evidence.
Journal ArticleDOI
Tight junction defects in patients with atopic dermatitis.
Anna De Benedetto,Nicholas Rafaels,Laura Y. McGirt,Andrei I. Ivanov,Steve N. Georas,Chris Cheadle,Alan E. Berger,Kunzhong Zhang,Sadasivan Vidyasagar,Takeshi Yoshida,Mark Boguniewicz,Tissa Hata,Lynda C. Schneider,Jon M. Hanifin,Richard L. Gallo,Natalija Novak,Stephan Weidinger,Terri H. Beaty,Donald Y.M. Leung,Kathleen C. Barnes,Lisa A. Beck +20 more
TL;DR: It is suggested that an impairment in tight junctions contributes to the barrier dysfunction and immune dysregulation observed in AD subjects and that this may be mediated in part by reductions in claudin-1.
Journal ArticleDOI
Efficacy and safety of dupilumab in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical treatments: a randomised, placebo-controlled, dose-ranging phase 2b trial.
Diamant Thaçi,Eric L. Simpson,Lisa A. Beck,Thomas Bieber,Andrew Blauvelt,Kim A. Papp,Weily Soong,Margitta Worm,Jacek C Szepietowski,Howard Sofen,M. Kawashima,Richard Wu,Steven P. Weinstein,Neil M.H. Graham,Gianluca Pirozzi,Ariel Teper,E. Rand Sutherland,Vera Mastey,Neil Stahl,George D. Yancopoulos,Marius Ardeleanu +20 more
TL;DR: Dupilumab improved clinical responses in adults with moderate-to-severe atopic dermatitis in a dose-dependent manner, without significant safety concerns, and shows that IL-4 and IL-13 are key drivers of atopic skinitis.
References
More filters
Journal ArticleDOI
Grading of the severity of atopic dermatitis.
G Rajka,T Langeland +1 more
TL;DR: A simple system for baseline grading the severity of atopic dermatitis in clinical work, which permits distinction between mild, moderate and severe atopic skin disease by means of a score summation using the rule of nine.
Journal ArticleDOI
Double-blind, controlled, crossover study of cyclosporin in adults with severe refractory atopic dermatitis
J. M. Sowden,J. Berth-Jones,J.S. Ross,Richard Motley,Ronald Marks,Andrew Yule Finlay,Mir-saeed Salek,R.A.C. Graham-Brown,B.R. Allen,Richard D.R. Camp +9 more
TL;DR: It is confirmed that cyclosporin is a safe and effective short-term treatment for severe, refractory atopic dermatitis.
Journal ArticleDOI
A 12-week study of tacrolimus ointment for the treatment of atopic dermatitis in pediatric patients.
Amy S. Paller,Lawrence F. Eichenfield,Donald Y.M. Leung,Daniel Stewart,Melanie Lewitt Appell +4 more
TL;DR: Both tacrolimus ointment concentrations (0.03% and 0.1%) were safe and significantly more effective than vehicle for the treatment of atopic dermatitis in children.
Journal ArticleDOI
Long-term safety and efficacy of tacrolimus ointment for the treatment of atopic dermatitis in children.
TL;DR: Tacrolimus ointment (0.1%) is safe and effective for long-term treatment of atopic dermatitis in children and was maintained with prolonged daily use.
Journal ArticleDOI
Tacrolimus ointment for the treatment of atopic dermatitis in adult patients: Part I, efficacy
TL;DR: Tacrolimus ointment-treated patients showed significantly greater improvement than vehicle- treated patients for all efficacy parameters evaluated, including the %BSA affected, the total score and individual scores for signs of atopic dermatitis, the patient's assessment of pruritus, and EASI score.
Related Papers (5)
Severity Scoring of Atopic Dermatitis: The SCORAD Index
K.U. Schallreuter,Ch. Levenig,J. Berger,J. Umbert,R.K. Winkelmann,L. Wegener,O. Correia,Olivier Chosidow,P. Saiag,S. Bastuji-Garin,J. Revuz,Jean-Claude Roujeau,R. Situ,D.R. Inman,S.E.G. Fligiel,J. Varani,R.E. Schopf,J. Dobmeyer,T. Dobmeyer,B. Morsches,K. Holubar,G.E. Piérard,O. Bongard,H. Bounameaux,P. Corcuff,J.-L. Lévêque,J. Brasch,E. Christophers,G.T. Nahass,M. Sisto,S.A. Wagner,R.U. Peter,O. Adam,T. Ruzicka,J. McGrath,N.P. Burrows,R. Russell Jones,R.A.J. Eady,S. Veraldi,G. Rizzitelli,G. Lunghi,R. Cardone,R.M. Trüeb,G. Burg,F. Wantke,G. Fleischl,M. Götz,R. Jarisch,G. Tadini,E. Ermacora,S. Cambiaghi,A. Brusasco,R. Cavalli +52 more